We are pleased to share the latest Community Letter issued by Roche, providing an update on their ongoing efforts in Spinal Muscular Atrophy (SMA) in 2024. The letter includes the latest developments on risdiplam and Roche’s SMA clinical development program.
Biohaven released the results from their RESILIENT SMA clinical trial, and they did not meet the primary endpoint. Biohaven is currently analysing the data further and is engaging in discussion with Health Authorities.
We're excited to announce that SMA News Today has featured our OdySMA real-life stories initiative, as part of their latest publication!
Today, December 5th, we join the global celebration of International Volunteers Day! SMA Europe extends heartfelt gratitude to our dedicated volunteers who generously devote their time and energy to driving positive change in the SMA community worldwide.